A ONCE-DAILY ORAL JAK inhibitor indicated for the treatment of adults and pediatric patients 12+ years of age with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.1

MONITORING

AND TREATMENT
CONSIDERATIONS

Perform lab testing for1:
Graph representing laboratory values and when they should be checked.

*According to guidelines for hyperlipidemia.

Interrupt treatment if patient develops a serious or opportunistic infection1

Treatment may be restarted when blood levels return to acceptable values seen in chart above, drug-induced liver diagnosis is excluded or infection is controlled.1

RINVOQ is not recommended for use in patients with severe hepatic impairment.1

Discontinue RINVOQ in patients that have experienced a myocardial infarction or stroke.1

Avoid RINVOQ in patients that may be at increased risk of thrombosis.1

Screen and periodically monitor for:
  • SERIOUS INFECTIONS1

    Closely monitor patients for the development of signs and symptoms of infection during and after treatment with RINVOQ.

  • TUBERCULOSIS1

    Monitor patients for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.

  • VIRAL REACTIVATION1

    Screening for viral hepatitis and monitoring for reactivation should be performed in accordance with clinical guidelines before starting and during therapy with RINVOQ.

  • PREGNANCY1

    Based on animal studies, RINVOQ may cause embryo-fetal toxicity when administered to pregnant women. Verify pregnancy status prior to starting treatment. Advise women to use effective contraception during and for 4 weeks after completion of treatment.

Lab abnormalities: placebo-controlled period through 16 weeks1,2

Graph representing lab values over time in placebo-controlled trials with patients on RINVOQ 15 mg and RINVOQ 30 mg.

Lipid elevations: Treatment with RINVOQ was associated with increases in lipid parameters, including total cholesterol, LDL cholesterol, and HDL cholesterol.

Includes subjects from M16-048, MEASURE UP 1, MEASURE UP 2, and AD UP.2
ALT=alanine aminotransferase; AST=aspartate transaminase; HDL=high-density lipoprotein; LDL=low-density lipoprotein; ULN=upper limit of normal.

Want to know more about treatment initiation and monitoring?